Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Sep 11 - Sep 16
Chen HM, Leung KW, Thakur NN, Tan A, Jack RW
They decrease pro-inflammatory cytokines such as TNF- and IL-6 and promote reparative M2 macrophage phenotypes that reduce fibrosis and maintain tissue architecture
Vial contents: 6 mg AOD-9604 + 3 mg CJC-1295 + 3 mg Ipamorelin (12 mg total)
These additional ingredients are known to potentiate the benefits of BPC-157, enhancing tissue repair and anti-inflammatory effects
They'll serve different niches: CagriSema Will Dominate: Patients familiar with Wegovy brand Those wanting proven semaglutide component People with type 2 diabetes (strong REIMAGINE data) Earlier availability (mid-2027) Retatrutide Will Dominate: Patients needing maximum weight loss (BMI 40) Those with multiple complications (OA + OSA + obesity) People who failed CagriSema Willingness to wait for highest efficacy Tirzepatide (Zepbound) Will Remain Relevant: Already available NOW Proven safety with 22.5% weight loss Lower cost than either new option Established insurance coverage The High-Dose CagriSema Wildcard Novo Nordisk announced plans for CagriSema 2.4mg/7.2mg trials starting late 2026tripling the cagrilintide dose
US$ 25.56
US$ 24.05
US$ 25.72
US$ 24.04
US$ 28.89